Feedback PLC Result of General Meeting (4990H)
November 15 2018 - 6:35AM
UK Regulatory
TIDMFDBK
RNS Number : 4990H
Feedback PLC
15 November 2018
15 November 2018
Feedback plc
Result of General Meeting
Cambridge, 15 November 2018: Feedback plc (AIM: FDBK, "Feedback"
or the "Company"), is pleased to announce that all resolutions put
to shareholders at the Company's General Meeting held earlier
today, were duly passed.
Accordingly, pursuant to the placing and subscription announced
on 25 October 2018, 36,200,000 new ordinary shares of 0.25p each
are expected to be admitted to trading on AIM tomorrow, 16 November
2018 ("Admission").
Total Voting Rights
On Admission, the Company will have 373,283,250 ordinary shares
of 0.25p in issue, each with one voting right. The Company does not
hold any shares in treasury. Therefore, the total number of
ordinary shares and voting rights in the Company will be
373,283,250.
From Admission, the above figure of 373,283,250 may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Enquiries:
Feedback plc +44 (0)1954 718072
Alastair Riddell, Executive Chairman IR@fbk.com
Lindsay Melvin, CFO
Allenby Capital Limited (Nominated Adviser)
David Worlidge / Asha Chotai +44 (0)20 3328 5656
Peterhouse Capital Limited (Joint Broker)
Lucy Williams / Duncan Vasey +44 (0)20 7469 0936
Stanford Capital Partners Limited (Joint +44 20 3815 8880
Broker)
Patrick Claridge / John Howes
+44 (0)20 7457 2020
Instinctif Partners feedbackplc@instinctif.com
Rozi Morris/ Deborah Bell/ Phillip Marriage
Notes to editors
About Feedback plc
Feedback plc (AIM: FDBK) is a specialist medical imaging
technology company providing innovative software and systems,
through its fully-owned trading subsidiary, Feedback Medical
Limited. Its products advance the work of radiologists, clinicians
and medical researchers by improving workflows and giving unique
insights into diseases, particularly cancer. Feedback Medical works
with customers globally from headquarters in the internationally
renowned scientific hub of Cambridge, UK. Its proprietary
technologies are TexRAD(R) , the quantitative texture analysis tool
and Cadran, a picture archiving communication system (PACS). For
more information, see www.fbk.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMGGGCWGUPRGGA
(END) Dow Jones Newswires
November 15, 2018 06:35 ET (11:35 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From Apr 2023 to Apr 2024